Could serum visfatin be a potential biomarker for postmenopausal breast cancer?

Maturitas

Volumn 71, Issue 3, 2012, Pages 301-308

  Dalamaga, Maria ^a,b   Archondakis, Stavros ^c   Sotiropoulos, George ^d   Karmaniolas, Konstantinos ^e   Pelekanos, Nicolaos ^a   Papadavid, Evangelia ^a   Lekka, Antigoni ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c Cytopathology Department   (Greece)

^d ATHENS NAVAL HOSPITAL   (Greece)

^e NIMTS HOSPITAL   (Greece)

Author keywords

Adipokine; Biomarker; Breast cancer; Postmenopausal; Visfatin

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROGESTERONE RECEPTOR;

ADULT; ANTHROPOMETRY; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; METABOLISM; POSTMENOPAUSE BREAST CANCER; RECEIVER OPERATING CHARACTERISTIC; VISFATIN BLOOD LEVEL;

AGED; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; NEOPLASM INVASIVENESS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; POSTMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84856975041     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.12.013     Document Type: Article

References (40)

1. V.G. Vogel Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer Menopause 15 2008 782 789
2. P. Pisani, F. Bray, and D.M. Parkin Estimates of the world-wide prevalence of cancer for 25 sites in the adult population Int J Cancer 97 2002 72 81
3. D.P. Rose, S.M. Haffner, and J. Baillargeon Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women Endocr Rev 28 2007 763 777 (Pubitemid 350294295)
4. D.A. Berry, K.A. Cronin, and S.K. Plevritis Effect of screening and adjuvant therapy on mortality from breast cancer N Engl J Med 353 2005 1784 1792 (Pubitemid 41549890)
5. D. Trichopoulos, H.-O. Adami, A. Ekbom, C.-C. Hsieh, and P. Lagiou Early life events and conditions and breast cancer risk: from epidemiology to etiology Int J Cancer 122 2008 481 485 (Pubitemid 350308937)
6. T.J. Key, P.K. Verkasalo, and E. Banks Epidemiology of breast cancer Lancet Oncol 2 2001 133 140 (Pubitemid 33585924)
7. E.S. Hwang, T. Chew, S. Shiboski, G. Farren, C.C. Benz, and M. Wrensch Risk factors for estrogen receptor-positive breast cancer Arch Surg 140 2005 58 62 (Pubitemid 40105063)
8. R.E. James, A. Lukanova, and L. Dossus Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study Cancer Prev Res 4 2011 1626 1635
9. D.P. Rose, D. Komninou, and G.D. Stephenson Obesity, adipocytokines, and insulin resistance in breast cancer Obesity Rev 5 2004 153 165 (Pubitemid 38998240)
10. S.W. Oh, C.Y. Park, and E.S. Lee Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study Breast Cancer Res 13 2 2011 R34
11. C. Mantzoros, E. Petridou, and N. Dessypris Adiponectin and breast cancer risk J Clin Endocrinol Metab 89 2004 1102 1107 (Pubitemid 38368397)
12. F. Xue, and K.B. Michels Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence Am J Clin Nutr 86 2007 s823 s835
13. M. Brooks Breast cancer screening and biomarkers Methods Mol Biol 472 2009 307 321
14. M.J. Duffy, D. Evoy, and E.W. McDermott CA 15-3: uses and limitation as a biomarker for breast cancer Clin Chim Acta 411 2010 1869 1874
15. M.J. Duffy Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52 2006 345 351
16. D.P. Rose, E.M. Gilhooly, and D.W. Nixon Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin Int J Oncol 21 2002 1285 1292
17. F. Ziemke, and C.S. Mantzoros Adiponectin in insulin resistance: lessons from translational research Am J Clin Nutr 91 2010 258 261
18. A. Garten, S. Petzold, A. Körner, S.-I. Imai, and W. Kiess Nampt: linking NAD biology, metabolism and cancer Trends Endocrinol Metab 20 2009 130 138
19. A.R. Moschen, R.R. Gerner, and H. Tilg Pre-B cell colony enhancing factor/Nampt/visfatin in inflammation and obesity-related disorders Curr Pharm Des 16 2010 1913 1920
20. S. Imai Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases Curr Pharm Des 15 2009 20 28
21. T.E. Nakajima, Y. Yamada, and T. Hamano Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer J Gastroenterol 44 2009 685 690
22. T.E. Nakajima, Y. Yamada, and T. Hamano Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer Cancer Sci 101 2010 1286 1291
23. M. Dalamaga, K. Karmaniolas, E. Papadavid, N. Pelekanos, G. Sotiropoulos, and A. Lekka Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters Menopause 18 2011 1198 1204
24. Y.-C. Lee, Y.-H. Yang, J.-H. Su, H.-L. Chang, M.-F. Hou, and S-S.F. Yuan High visfatin expression in breast cancer tissue is associated with poor survival Cancer Epidemiol Biomarkers Prev 2011 1892 1901
25. M. Dalamaga, K. Karmaniolas, F. Kontos, I. Migdalis, and A. Dionyssiou-Asteriou Clinical study on the serum carcinoembryonic antigen, CA 19-9, CA 50, and alpha-fetoprotein levels in patients with myelodysplastic syndromes Leuk Lymphoma 47 2006 1782 1787 (Pubitemid 44649760)
26. T.E. Nakajima, Y. Yamada, and T. Hamano Adipocytokines and squamous cell carcinoma of the esophagus J Cancer Res Clin Oncol 136 2010 261 266
27. S.E. Hufton, P.T. Moerkerk, R. Brandwijk, A.P. de Bruine, J.W. Arends, and H.R. Hoogenboom A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization FEBS Lett 463 1999 77 82 (Pubitemid 30001722)
28. S.-K. Bae, S.-R. Kim, and J.G. Kim Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1 FEBS Lett 580 2006 4105 4113 (Pubitemid 44037574)
29. M.A. Folgueira, D.M. Carraro, and H. Brantani Gene expression profile associated with response to doxorubicin-based therapy in breast cancer Clin Cancer Res 11 2005 7434 7443 (Pubitemid 41507704)
30. S.T. Patel, T. Mistry, and J.E.P. Brown A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis Peptides 31 2010 51 57
31. S.S. Tworoger, A.H. Eliassen, and T. Kelesidis Plasma adiponectin concentrations and risk of incident breast cancer J Clin Endocrinol Metab 92 2007 1510 1516 (Pubitemid 46556432)
32. I. Kelesidis, T. Kelesidis, and C.S. Mantzoros Adiponectin and cancer: a systematic review Br J Cancer 94 2006 1221 1225
33. U.H. Olesen, M.K. Christensen, and F. Björkling Anticancer agent CHS-828 inhibits cellular synthesis of NAD Biochem Biophys Res Commun 367 2008 799 804
34. J.G. Kim, E.O. Kim, and B.R. Jeong Visfatin stimulates proliferation of MCF7 human breast cancer cells Mol Cells 30 2010 341 345
35. J. Zhou, and E.R. Seidel Estrogens induce visfatin expression in 3T3-L1 cells Peptides 31 2010 271 274
36. B. Zahorska-Markiewicz, Olszanecka-Glinianowicz, and J. Janowska Serum concentration of visfatin in obese women Metabolism 2007 1131 1134 (Pubitemid 47021180)
37. K. Oki, K. Yamane, N. Kami, H. Nojima, and N. Kohno Circulating visfatin level is correlated with inflammation, but not with insulin resistance Clin Endocrinol 67 2007 796 800 (Pubitemid 47628470)
38. C.C. Chen, T.C. Li, and C.I. Li The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women Metabolism 56 2007 1216 1220
39. M. Dalamaga, K. Karmaniolas, and A. Panagiotou Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study Cancer Causes Control 20 2009 193 199
40. M. Dalamaga, K. Karmaniolas, and A. Nikolaidou Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system Eur J Cancer 44 2008 1744 1753